首页 > 最新文献

Cancer Science最新文献

英文 中文
The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era. 基因分类时代 DLBCL 中 MYC/BCL2 双重表达的预后意义。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-04 DOI: 10.1111/cas.16377
Yi-Fan Wu, Qun-Hui Yuan, Hao-Rui Shen, Kai-Xin Du, Chun-Yu Shang, Yue Li, Xin-Yu Zhang, Jia-Zhu Wu, Rui Gao, Li Wang, Jian-Yong Li, Hua Yin, Jin-Hua Liang, Wei Xu

Double expression (DE) is a World Health Organization-recognized adverse prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, the prognostic value of DE in the genetic subtyping era and potential mechanisms remain to be explored. We enrolled 246 DLBCL patients diagnosed between December 2021 and September 2023 in a Jiangsu Province Hospital cohort and included 930 DLBCL patients from three published studies in an external cohort. Double-expression DLBCL (DEL) in the external cohort was mainly distributed in the OTHER subtype (42.0%), EZB subtype (28.3%), and MCD subtype (15.0%), whereas the MCD subtype exhibited the highest ratio of DEL. DEL was significantly related to unfavorable overall survival (OS) and progression-free survival (PFS) in DLBCL, but only in EZB and OTHER subtypes that DEL retained remarkably adverse impacts on survivals compared to non-DEL. We explored the prognostic value of clinical and genetic parameters in DEL patients and found only ST2 showed better OS than A53 in DEL patients, whereas the other subtypes showed no significant difference. DEL showed similarities with the MCD subtype in mutation profiles. Furthermore, RNA-sequencing analyses exhibited upregulation in tumor proliferation-related pathways in DEL patients, but downregulation in extracellular matrix organization, T-cell activation and proliferation, type II interferon production, and pathways associated with cell death might contribute to the poor outcomes of DEL patients.

双重表达(DE)是世界卫生组织公认的弥漫大B细胞淋巴瘤(DLBCL)的不良预后因素。然而,DE在基因亚型时代的预后价值和潜在机制仍有待探索。我们在江苏省医院的队列中纳入了2021年12月至2023年9月期间确诊的246例DLBCL患者,并在外部队列中纳入了来自三项已发表研究的930例DLBCL患者。外部队列中的双表达DLBCL(DEL)主要分布于OTHER亚型(42.0%)、EZB亚型(28.3%)和MCD亚型(15.0%),而MCD亚型的DEL比例最高。在DLBCL中,DEL与不利的总生存期(OS)和无进展生存期(PFS)明显相关,但只有在EZB和OTHER亚型中,与非DEL相比,DEL才对生存期有明显的不利影响。我们探讨了DEL患者临床和遗传参数的预后价值,发现在DEL患者中,只有ST2的OS优于A53,而其他亚型无明显差异。DEL与MCD亚型在突变特征上有相似之处。此外,RNA序列分析显示,DEL患者肿瘤增殖相关通路上调,但细胞外基质组织、T细胞活化和增殖、II型干扰素产生以及细胞死亡相关通路下调,这可能是导致DEL患者预后不佳的原因。
{"title":"The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era.","authors":"Yi-Fan Wu, Qun-Hui Yuan, Hao-Rui Shen, Kai-Xin Du, Chun-Yu Shang, Yue Li, Xin-Yu Zhang, Jia-Zhu Wu, Rui Gao, Li Wang, Jian-Yong Li, Hua Yin, Jin-Hua Liang, Wei Xu","doi":"10.1111/cas.16377","DOIUrl":"https://doi.org/10.1111/cas.16377","url":null,"abstract":"<p><p>Double expression (DE) is a World Health Organization-recognized adverse prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, the prognostic value of DE in the genetic subtyping era and potential mechanisms remain to be explored. We enrolled 246 DLBCL patients diagnosed between December 2021 and September 2023 in a Jiangsu Province Hospital cohort and included 930 DLBCL patients from three published studies in an external cohort. Double-expression DLBCL (DEL) in the external cohort was mainly distributed in the OTHER subtype (42.0%), EZB subtype (28.3%), and MCD subtype (15.0%), whereas the MCD subtype exhibited the highest ratio of DEL. DEL was significantly related to unfavorable overall survival (OS) and progression-free survival (PFS) in DLBCL, but only in EZB and OTHER subtypes that DEL retained remarkably adverse impacts on survivals compared to non-DEL. We explored the prognostic value of clinical and genetic parameters in DEL patients and found only ST2 showed better OS than A53 in DEL patients, whereas the other subtypes showed no significant difference. DEL showed similarities with the MCD subtype in mutation profiles. Furthermore, RNA-sequencing analyses exhibited upregulation in tumor proliferation-related pathways in DEL patients, but downregulation in extracellular matrix organization, T-cell activation and proliferation, type II interferon production, and pathways associated with cell death might contribute to the poor outcomes of DEL patients.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibrocytes in tumor microenvironment: Identification of their fraction and novel therapeutic strategy. 肿瘤微环境中的纤维细胞:确定纤维细胞的组成和新型治疗策略
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-04 DOI: 10.1111/cas.16385
Atsushi Mitsuhashi, Yasuhiko Nishioka

Fibrocytes were identified as bone marrow-derived myeloid cells that also have fibroblast-like phenotypes, such as ECM production and differentiation to myofibroblasts. Although fibrocytes are known to contribute to various types of tissue fibrosis, their functions in the tumor microenvironment are unclear. We focused on fibrocytes as pivotal regulators of tumor progression. Our previous studies have indicated that fibrocytes induce angiogenesis and cancer stem cell-like phenotypes by secreting various growth factors. In contrast, immune checkpoint inhibitor (ICI)-treated fibrocytes demonstrated antigen-presenting capacity and enhanced antitumor T cell proliferation. Taken together, these findings indicate that fibrocytes have multiple effects on tumor progression. However, the detailed phenotypes of fibrocytes have not been fully elucidated because the isolation of distinct fibrocyte clusters has not been achieved without culturing in ECM-coated conditions or intracellular staining of ECM. The development of single-cell analyses partially resolves these problems. Single-cell RNA sequences in CD45+ immune cells from tumor tissue identified ECM-expressing myeloid-like cells as distinct fibrocyte clusters. In addition, these findings enabled the isolation of tumor-infiltrating fibrocytes as CD45+CD34+ cells. These tumor-infiltrating fibrocytes demonstrated both antigen-presenting ability and differentiation into myofibroblast-like cancer-associated fibroblasts. Considering these functions of fibrocytes in tumor progression, molecular-targeting agents for the migration, activity, and differentiation of fibrocytes are promising therapeutic strategies. Furthermore, identification of specific cell surface markers and master regulators of fibrocytes will advance novel fibrocyte-targeting therapies. In this review, we discuss the multiple roles of tumor-infiltrating fibrocytes and novel cancer therapeutic strategies.

纤维细胞被鉴定为骨髓来源的髓样细胞,也具有类似成纤维细胞的表型,如产生 ECM 和分化为肌成纤维细胞。尽管已知成纤维细胞可导致各种类型的组织纤维化,但它们在肿瘤微环境中的功能尚不清楚。我们重点研究了作为肿瘤进展关键调节因子的纤维细胞。我们之前的研究表明,纤维细胞通过分泌各种生长因子诱导血管生成和癌症干细胞样表型。相反,免疫检查点抑制剂(ICI)处理过的纤维细胞具有抗原递呈能力,并能增强抗肿瘤 T 细胞的增殖。总之,这些研究结果表明,纤维细胞对肿瘤的进展有多重影响。然而,纤维细胞的详细表型尚未完全阐明,因为如果不在涂有 ECM 的条件下培养或不对 ECM 进行细胞内染色,就无法分离出不同的纤维细胞簇。单细胞分析技术的发展部分解决了这些问题。肿瘤组织中 CD45+ 免疫细胞的单细胞 RNA 序列确定了表达 ECM 的髓样细胞是独特的纤维细胞集群。此外,这些发现还能将肿瘤浸润纤维细胞分离为 CD45+CD34+ 细胞。这些肿瘤浸润纤维细胞既具有抗原递呈能力,又能分化为肌成纤维细胞样癌症相关成纤维细胞。考虑到纤维细胞在肿瘤进展中的这些功能,针对纤维细胞迁移、活性和分化的分子靶向药物是很有前景的治疗策略。此外,特异性细胞表面标志物和纤维细胞主调控因子的鉴定将推动新型纤维细胞靶向疗法的发展。在这篇综述中,我们将讨论肿瘤浸润纤维细胞的多重作用和新型癌症治疗策略。
{"title":"Fibrocytes in tumor microenvironment: Identification of their fraction and novel therapeutic strategy.","authors":"Atsushi Mitsuhashi, Yasuhiko Nishioka","doi":"10.1111/cas.16385","DOIUrl":"https://doi.org/10.1111/cas.16385","url":null,"abstract":"<p><p>Fibrocytes were identified as bone marrow-derived myeloid cells that also have fibroblast-like phenotypes, such as ECM production and differentiation to myofibroblasts. Although fibrocytes are known to contribute to various types of tissue fibrosis, their functions in the tumor microenvironment are unclear. We focused on fibrocytes as pivotal regulators of tumor progression. Our previous studies have indicated that fibrocytes induce angiogenesis and cancer stem cell-like phenotypes by secreting various growth factors. In contrast, immune checkpoint inhibitor (ICI)-treated fibrocytes demonstrated antigen-presenting capacity and enhanced antitumor T cell proliferation. Taken together, these findings indicate that fibrocytes have multiple effects on tumor progression. However, the detailed phenotypes of fibrocytes have not been fully elucidated because the isolation of distinct fibrocyte clusters has not been achieved without culturing in ECM-coated conditions or intracellular staining of ECM. The development of single-cell analyses partially resolves these problems. Single-cell RNA sequences in CD45<sup>+</sup> immune cells from tumor tissue identified ECM-expressing myeloid-like cells as distinct fibrocyte clusters. In addition, these findings enabled the isolation of tumor-infiltrating fibrocytes as CD45<sup>+</sup>CD34<sup>+</sup> cells. These tumor-infiltrating fibrocytes demonstrated both antigen-presenting ability and differentiation into myofibroblast-like cancer-associated fibroblasts. Considering these functions of fibrocytes in tumor progression, molecular-targeting agents for the migration, activity, and differentiation of fibrocytes are promising therapeutic strategies. Furthermore, identification of specific cell surface markers and master regulators of fibrocytes will advance novel fibrocyte-targeting therapies. In this review, we discuss the multiple roles of tumor-infiltrating fibrocytes and novel cancer therapeutic strategies.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
METTL14 attenuates cancer stemness by suppressing ATF5/WDR74/β-catenin axis in gastric cancer. METTL14通过抑制胃癌中的ATF5/WDR74/β-catenin轴减轻癌症干性。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-04 DOI: 10.1111/cas.16381
Peiling Zhang, Hong Xiang, Qian Peng, Lujuan Ma, Chengyin Weng, Guolong Liu, Lin Lu

Stemness is a key factor contributing to treatment failure in gastric cancer (GC). Methyltransferase-like 14 (METTL14) has been linked to various cancers, though its specific role in regulating stemness in GC remains undefined. In this study, we assessed METTL14 expression levels in GC tissues using public datasets and clinical specimens and investigated its impact on cell proliferation, metastasis, and stemness both in vitro and in vivo. Through m6A RNA immunoprecipitation (MeRIP) and luciferase reporter assays, we identified downstream targets of METTL14. Rescue assays were performed to examine whether METTL14 overexpression could reverse stemness in GC. We also explored the underlying mechanisms using chromatin immunoprecipitation (ChIP) and western blot analysis, focusing on the role of ATF5 and the upstream regulation of METTL14. Our findings show that lower METTL14 expression is associated with poorer overall survival in GC patients. Functionally, METTL14 knockdown enhanced stemness traits in GC cells. Mechanistically, METTL14 facilitated m6A modification, promoting the degradation of ATF5 mRNA. Overexpression of ATF5 reversed the stemness inhibition caused by METTL14 overexpression by increasing WDR74 transcription and enhancing β-catenin nuclear translocation. Furthermore, histone H3 lactylation at Lys18 was found to upregulate METTL14 expression. In conclusion, METTL14 knockdown promotes stemness in GC by mediating m6A modification of ATF5 mRNA, which activates the WDR74/β-catenin axis, making METTL14 a potential therapeutic target for gastric cancer treatment.

干细胞是导致胃癌(GC)治疗失败的一个关键因素。甲基转移酶样14(METTL14)与多种癌症有关,但它在调节胃癌干性中的具体作用仍未确定。在这项研究中,我们利用公共数据集和临床标本评估了METTL14在GC组织中的表达水平,并研究了它在体外和体内对细胞增殖、转移和干性的影响。通过m6A RNA免疫沉淀(MeRIP)和荧光素酶报告实验,我们确定了METTL14的下游靶标。我们还进行了拯救试验,以检验 METTL14 的过表达是否能逆转 GC 的干性。我们还利用染色质免疫沉淀(ChIP)和Western印迹分析探讨了其潜在机制,重点研究了ATF5的作用和METTL14的上游调控。我们的研究结果表明,METTL14的低表达与GC患者较差的总生存率有关。在功能上,METTL14的敲除增强了GC细胞的干性特征。从机理上讲,METTL14有助于m6A修饰,促进ATF5 mRNA的降解。ATF5的过表达通过增加WDR74的转录和增强β-catenin的核转位,逆转了METTL14过表达导致的干性抑制。此外,研究还发现组蛋白H3在Lys18处的乳酰化能上调METTL14的表达。总之,METTL14基因敲除通过介导ATF5 mRNA的m6A修饰,激活WDR74/β-catenin轴,从而促进GC的干性,使METTL14成为治疗胃癌的潜在靶点。
{"title":"METTL14 attenuates cancer stemness by suppressing ATF5/WDR74/β-catenin axis in gastric cancer.","authors":"Peiling Zhang, Hong Xiang, Qian Peng, Lujuan Ma, Chengyin Weng, Guolong Liu, Lin Lu","doi":"10.1111/cas.16381","DOIUrl":"https://doi.org/10.1111/cas.16381","url":null,"abstract":"<p><p>Stemness is a key factor contributing to treatment failure in gastric cancer (GC). Methyltransferase-like 14 (METTL14) has been linked to various cancers, though its specific role in regulating stemness in GC remains undefined. In this study, we assessed METTL14 expression levels in GC tissues using public datasets and clinical specimens and investigated its impact on cell proliferation, metastasis, and stemness both in vitro and in vivo. Through m6A RNA immunoprecipitation (MeRIP) and luciferase reporter assays, we identified downstream targets of METTL14. Rescue assays were performed to examine whether METTL14 overexpression could reverse stemness in GC. We also explored the underlying mechanisms using chromatin immunoprecipitation (ChIP) and western blot analysis, focusing on the role of ATF5 and the upstream regulation of METTL14. Our findings show that lower METTL14 expression is associated with poorer overall survival in GC patients. Functionally, METTL14 knockdown enhanced stemness traits in GC cells. Mechanistically, METTL14 facilitated m6A modification, promoting the degradation of ATF5 mRNA. Overexpression of ATF5 reversed the stemness inhibition caused by METTL14 overexpression by increasing WDR74 transcription and enhancing β-catenin nuclear translocation. Furthermore, histone H3 lactylation at Lys18 was found to upregulate METTL14 expression. In conclusion, METTL14 knockdown promotes stemness in GC by mediating m6A modification of ATF5 mRNA, which activates the WDR74/β-catenin axis, making METTL14 a potential therapeutic target for gastric cancer treatment.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. Camrelizumab 联合吉西他滨和阿帕替尼治疗晚期 PD-L1 阳性胆道癌。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-03 DOI: 10.1111/cas.16376
Yitong Tian, Changxian Li, Ke Jin, Ling Ma, Jiaguang Zhang, Xinyi Zhang, Wei You, Haoyang Shen, Yuting Ding, Hao Qian, Xiangcheng Li, Xiaofeng Chen

The efficacy of combined chemotherapy and immunotherapy has previously been demonstrated in patients with biliary tract cancer. The aim of this study was to assess the efficacy and safety of camrelizumab in combination with gemcitabine and apatinib as a first- or second-line treatment for advanced programmed death-ligand 1 (PD-L1)-positive biliary tract cancer. This prospective, single-arm, and exploratory clinical trial aimed at recruiting 20 PD-L1-positive patients (tumor proportion score ≥1% or combined positive score ≥1) who met the inclusion criteria. Camrelizumab (200 mg) was administered in combination with gemcitabine (800 mg/m2) and apatinib (250 mg). The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Fourteen patients were enrolled between September 2, 2020, and December 15, 2022. At the data cutoff on August 16, 2023, the median follow-up time was 11.4 months (interquartile range, 4.5-15.4), with one patient still undergoing treatment. Among the enrolled patients, six achieved a partial response, and four had stable disease. The ORR was 42.9% (95% confidence interval [CI], 17.7-71.1), and the DCR was 71.4% (95% CI, 41.9-91.6). The median PFS was 5.4 months (95% CI, 2.8-not reached), and the median OS was 13.5 months (95% CI, 5.7-not reached). The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.

化疗和免疫疗法联合治疗胆道癌的疗效已在胆道癌患者中得到证实。本研究旨在评估坎瑞珠单抗联合吉西他滨和阿帕替尼作为晚期程序性死亡配体1(PD-L1)阳性胆道癌一线或二线治疗的有效性和安全性。这项前瞻性、单臂、探索性临床试验旨在招募20名符合纳入标准的PD-L1阳性患者(肿瘤比例评分≥1%或合并阳性评分≥1)。康瑞珠单抗(200 毫克)与吉西他滨(800 毫克/平方米)和阿帕替尼(250 毫克)联用。主要终点是客观反应率(ORR),次要终点是无进展生存期(PFS)、总生存期(OS)、疾病控制率(DCR)和安全性。14 名患者于 2020 年 9 月 2 日至 2022 年 12 月 15 日期间入组。数据截止日期为2023年8月16日,中位随访时间为11.4个月(四分位间范围为4.5-15.4),其中一名患者仍在接受治疗。在入组患者中,6 人获得部分应答,4 人病情稳定。ORR为42.9%(95%置信区间[CI],17.7-71.1),DCR为71.4%(95%置信区间[CI],41.9-91.6)。中位 PFS 为 5.4 个月(95% CI,2.8-未达标),中位 OS 为 13.5 个月(95% CI,5.7-未达标)。最常见的3级或4级治疗相关不良事件是中性粒细胞减少(4例,29%)。坎瑞珠单抗、吉西他滨和阿帕替尼联合疗法在晚期PD-L1阳性胆道癌患者中显示出良好的疗效和可接受的安全性。
{"title":"Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.","authors":"Yitong Tian, Changxian Li, Ke Jin, Ling Ma, Jiaguang Zhang, Xinyi Zhang, Wei You, Haoyang Shen, Yuting Ding, Hao Qian, Xiangcheng Li, Xiaofeng Chen","doi":"10.1111/cas.16376","DOIUrl":"https://doi.org/10.1111/cas.16376","url":null,"abstract":"<p><p>The efficacy of combined chemotherapy and immunotherapy has previously been demonstrated in patients with biliary tract cancer. The aim of this study was to assess the efficacy and safety of camrelizumab in combination with gemcitabine and apatinib as a first- or second-line treatment for advanced programmed death-ligand 1 (PD-L1)-positive biliary tract cancer. This prospective, single-arm, and exploratory clinical trial aimed at recruiting 20 PD-L1-positive patients (tumor proportion score ≥1% or combined positive score ≥1) who met the inclusion criteria. Camrelizumab (200 mg) was administered in combination with gemcitabine (800 mg/m<sup>2</sup>) and apatinib (250 mg). The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Fourteen patients were enrolled between September 2, 2020, and December 15, 2022. At the data cutoff on August 16, 2023, the median follow-up time was 11.4 months (interquartile range, 4.5-15.4), with one patient still undergoing treatment. Among the enrolled patients, six achieved a partial response, and four had stable disease. The ORR was 42.9% (95% confidence interval [CI], 17.7-71.1), and the DCR was 71.4% (95% CI, 41.9-91.6). The median PFS was 5.4 months (95% CI, 2.8-not reached), and the median OS was 13.5 months (95% CI, 5.7-not reached). The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes. 基于SARS-COV-2和肺腺癌串联基因的综合机器学习预测肺腺癌患者的预后。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-03 DOI: 10.1111/cas.16384
Yanan Wu, Yishuang Cui, Xuan Zheng, Xuemin Yao, Guogui Sun

Viruses are widely recognized to be intricately associated with both solid and hematological malignancies in humans. The primary goal of this research is to elucidate the interplay of genes between SARS-CoV-2 infection and lung adenocarcinoma (LUAD), with a preliminary investigation into their clinical significance and underlying molecular mechanisms. Transcriptome data for SARS-CoV-2 infection and LUAD were sourced from public databases. Differentially expressed genes (DEGs) associated with SARS-CoV-2 infection were identified and subsequently overlapped with TCGA-LUAD DEGs to discern the crosstalk genes (CGs). In addition, CGs pertaining to both diseases were further refined using LUAD TCGA and GEO datasets. Univariate Cox regression was conducted to identify genes associated with LUAD prognosis, and these genes were subsequently incorporated into the construction of a prognosis signature using 10 different machine learning algorithms. Additional investigations, including tumor mutation burden assessment, TME landscape, immunotherapy response assessment, as well as analysis of sensitivity to antitumor drugs, were also undertaken. We discovered the risk stratification based on the prognostic signature revealed that the low-risk group demonstrated superior clinical outcomes (p < 0.001). Gene set enrichment analysis results predominantly exhibited enrichment in pathways related to cell cycle. Our analyses also indicated that the low-risk group displayed elevated levels of infiltration by immunocytes (p < 0.001) and superior immunotherapy response (p < 0.001). In our study, we reveal a close association between CGs and the immune microenvironment of LUAD. This provides preliminary insight for further exploring the mechanism and interaction between the two diseases.

人们普遍认为,病毒与人类实体瘤和血液恶性肿瘤之间存在着错综复杂的联系。本研究的主要目的是阐明SARS-CoV-2感染与肺腺癌(LUAD)之间基因的相互作用,并对其临床意义和潜在的分子机制进行初步研究。SARS-CoV-2 感染和肺腺癌的转录组数据来自公共数据库。确定了与SARS-CoV-2感染相关的差异表达基因(DEGs),随后将其与TCGA-LUAD的DEGs重叠,以发现串联基因(CGs)。此外,还利用 LUAD TCGA 和 GEO 数据集进一步完善了与这两种疾病相关的 CGs。通过单变量考克斯回归确定了与LUAD预后相关的基因,随后使用10种不同的机器学习算法将这些基因纳入到预后特征的构建中。此外还进行了其他调查,包括肿瘤突变负荷评估、TME情况、免疫疗法反应评估以及抗肿瘤药物敏感性分析。我们发现,根据预后特征进行的风险分层显示,低风险组的临床疗效更好(p
{"title":"Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.","authors":"Yanan Wu, Yishuang Cui, Xuan Zheng, Xuemin Yao, Guogui Sun","doi":"10.1111/cas.16384","DOIUrl":"https://doi.org/10.1111/cas.16384","url":null,"abstract":"<p><p>Viruses are widely recognized to be intricately associated with both solid and hematological malignancies in humans. The primary goal of this research is to elucidate the interplay of genes between SARS-CoV-2 infection and lung adenocarcinoma (LUAD), with a preliminary investigation into their clinical significance and underlying molecular mechanisms. Transcriptome data for SARS-CoV-2 infection and LUAD were sourced from public databases. Differentially expressed genes (DEGs) associated with SARS-CoV-2 infection were identified and subsequently overlapped with TCGA-LUAD DEGs to discern the crosstalk genes (CGs). In addition, CGs pertaining to both diseases were further refined using LUAD TCGA and GEO datasets. Univariate Cox regression was conducted to identify genes associated with LUAD prognosis, and these genes were subsequently incorporated into the construction of a prognosis signature using 10 different machine learning algorithms. Additional investigations, including tumor mutation burden assessment, TME landscape, immunotherapy response assessment, as well as analysis of sensitivity to antitumor drugs, were also undertaken. We discovered the risk stratification based on the prognostic signature revealed that the low-risk group demonstrated superior clinical outcomes (p < 0.001). Gene set enrichment analysis results predominantly exhibited enrichment in pathways related to cell cycle. Our analyses also indicated that the low-risk group displayed elevated levels of infiltration by immunocytes (p < 0.001) and superior immunotherapy response (p < 0.001). In our study, we reveal a close association between CGs and the immune microenvironment of LUAD. This provides preliminary insight for further exploring the mechanism and interaction between the two diseases.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix. 酵母颗粒蛋白16B(ZG16B)是一种可用于调节乳腺细胞外基质的药物表观遗传靶标。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-03 DOI: 10.1111/cas.16382
Máté Lengyel, Ádám Molnár, Tamás Nagy, Sham Jdeed, Ildikó Garai, Zsolt Horváth, Iván P Uray

High tissue density of the mammary gland is considered a pro-tumorigenic factor, hence suppressing the stimuli that induce matrix buildup carries the potential for cancer interception. We found that in non-malignant mammary epithelial cells the combination of the chemopreventive agents bexarotene (Bex) and carvedilol (Carv) suppresses the zymogen granule protein 16B (ZG16B, PAUF) through an interaction of ARID1A with a proximal enhancer. Bex + Carv also reduced ZG16B levels in vivo in normal breast tissue and MDA-MB231 tumor xenografts. The relevance of ZG16B is underscored by ongoing clinical trials targeting ZG16B in pancreatic cancers, but its role in breast cancer development is unclear. In immortalized mammary epithelial cells, secreted recombinant ZG16B stimulated mitogenic kinase phosphorylation, detachment and mesenchymal characteristics, and promoted proliferation, motility and clonogenic growth. Highly concerted induction of specific laminin, collagen and integrin isoforms indicated a shift in matrix properties toward increased density and cell-matrix interactions. Exogenous ZG16B alone blocked Bex + Carv-mediated control of cell growth and migration, and antagonized Bex + Carv-induced gene programs regulating cell adhesion and migration. In breast cancer cells ZG16B induced colony formation and anchorage-independent growth, and stimulated migration in a PI3K/Akt-dependent manner. In contrast, Bex + Carv inhibited colony formation, reduced Ki67 levels, ZG16B expression and glucose uptake in MDA-MB231 xenografts. These data establish ZG16B as a druggable pro-tumorigenic target in breast cell transformation and suggest a key role of the matrisome network in rexinoid-dependent antitumor activity.

乳腺组织的高密度被认为是一种致癌因素,因此抑制诱导基质堆积的刺激物具有抑制癌症的潜力。我们发现,在非恶性乳腺上皮细胞中,化学预防剂贝沙罗汀(Bex)和卡维地洛(Carv)的组合能通过 ARID1A 与近端增强子的相互作用抑制酶原颗粒蛋白 16B(ZG16B,PAUF)。Bex + Carv 还降低了正常乳腺组织和 MDA-MB231 肿瘤异种移植体内的 ZG16B 水平。正在进行的针对胰腺癌的临床试验强调了 ZG16B 的相关性,但它在乳腺癌发展中的作用尚不清楚。在永生化乳腺上皮细胞中,分泌的重组 ZG16B 可刺激有丝分裂激酶磷酸化、脱落和间质特征,并促进增殖、运动和克隆性生长。对特定层粘蛋白、胶原蛋白和整合素同工酶的高度协同诱导表明,基质特性向密度增加和细胞-基质相互作用转变。单用外源 ZG16B 可阻断 Bex + Carv 介导的细胞生长和迁移控制,并拮抗 Bex + Carv 诱导的细胞粘附和迁移基因程序。在乳腺癌细胞中,ZG16B 以 PI3K/Akt 依赖性方式诱导集落形成和不依赖锚定的生长,并刺激迁移。与此相反,Bex + Carv 可抑制 MDA-MB231 异种移植中的集落形成,降低 Ki67 水平、ZG16B 表达和葡萄糖摄取。这些数据确立了 ZG16B 在乳腺细胞转化过程中是一个可药用的致癌靶点,并表明母体网络在雷公藤依赖性抗肿瘤活性中发挥着关键作用。
{"title":"Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix.","authors":"Máté Lengyel, Ádám Molnár, Tamás Nagy, Sham Jdeed, Ildikó Garai, Zsolt Horváth, Iván P Uray","doi":"10.1111/cas.16382","DOIUrl":"https://doi.org/10.1111/cas.16382","url":null,"abstract":"<p><p>High tissue density of the mammary gland is considered a pro-tumorigenic factor, hence suppressing the stimuli that induce matrix buildup carries the potential for cancer interception. We found that in non-malignant mammary epithelial cells the combination of the chemopreventive agents bexarotene (Bex) and carvedilol (Carv) suppresses the zymogen granule protein 16B (ZG16B, PAUF) through an interaction of ARID1A with a proximal enhancer. Bex + Carv also reduced ZG16B levels in vivo in normal breast tissue and MDA-MB231 tumor xenografts. The relevance of ZG16B is underscored by ongoing clinical trials targeting ZG16B in pancreatic cancers, but its role in breast cancer development is unclear. In immortalized mammary epithelial cells, secreted recombinant ZG16B stimulated mitogenic kinase phosphorylation, detachment and mesenchymal characteristics, and promoted proliferation, motility and clonogenic growth. Highly concerted induction of specific laminin, collagen and integrin isoforms indicated a shift in matrix properties toward increased density and cell-matrix interactions. Exogenous ZG16B alone blocked Bex + Carv-mediated control of cell growth and migration, and antagonized Bex + Carv-induced gene programs regulating cell adhesion and migration. In breast cancer cells ZG16B induced colony formation and anchorage-independent growth, and stimulated migration in a PI3K/Akt-dependent manner. In contrast, Bex + Carv inhibited colony formation, reduced Ki67 levels, ZG16B expression and glucose uptake in MDA-MB231 xenografts. These data establish ZG16B as a druggable pro-tumorigenic target in breast cell transformation and suggest a key role of the matrisome network in rexinoid-dependent antitumor activity.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in noncoding RNA modifications of gastrointestinal cancer. 胃肠癌非编码 RNA 修饰的最新进展。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.1111/cas.16380
Tomoaki Hara, Sikun Meng, Yasuko Arao, Yoshiko Saito, Kana Inoue, Sarah Rennie, Ken Ofusa, Yuichiro Doki, Hidetoshi Eguchi, Toru Kitagawa, Hideshi Ishii

Elucidating the mechanisms underlying cancer development and proliferation is important for the development of therapeutic methods for the complete cure of cancer. In particular, the identification of diagnostic markers for early detection and new therapeutic strategies for refractory gastrointestinal cancers are needed. Various abnormal phenomena occur in cancer cells, such as functional changes of proteins, led by genomic mutations, and changes in gene expression due to dysregulation of epigenetic regulation. This is no exception for noncoding RNA (ncRNA), which do not encode proteins. Recent reports have revealed that microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA) are deeply involved in cancer progression. These ncRNAs have attracted attention as gene expression regulatory molecules. Recent advances in technology have made it possible not only to read DNA and RNA sequences but also to study the modification state of each base. In particular, comprehensive analysis of N6-methyladenosine (m6A) has been performed by many research groups, with multiple studies reporting that m6A modifications of specific genes are associated with cancer progression. Based on the above, this review examines how ncRNA modifications are related to cancer progression in gastrointestinal cancers such as colorectal and pancreatic cancer. We also discuss enzyme inhibitors that have been reported to have drug discovery potential targeting m6A modifications. By utilizing the new perspective of ncRNA modification, we may be able to accumulate knowledge on the molecular biology of cancer and contribute to human health through diagnosis and treatment.

阐明癌症发展和增殖的内在机制对于开发彻底治愈癌症的治疗方法非常重要。特别是,需要为难治性胃肠道癌症确定早期检测的诊断标志物和新的治疗策略。癌细胞中会出现各种异常现象,如基因组突变导致的蛋白质功能变化,以及表观遗传调控失调导致的基因表达变化。不编码蛋白质的非编码 RNA(ncRNA)也不例外。最近的报告显示,微小核糖核酸(miRNA)、长非编码核糖核酸(lncRNA)和环状核糖核酸(circRNA)与癌症的进展有密切关系。这些 ncRNA 作为基因表达调控分子备受关注。近来技术的进步使我们不仅能读取 DNA 和 RNA 序列,还能研究每个碱基的修饰状态。特别是,许多研究小组对 N6-甲基腺苷(m6A)进行了全面分析,多项研究报告称,特定基因的 m6A 修饰与癌症进展有关。在此基础上,本综述探讨了 ncRNA 修饰与结直肠癌和胰腺癌等胃肠道癌症的进展有何关系。我们还讨论了据报道具有药物开发潜力的针对 m6A 修饰的酶抑制剂。通过利用 ncRNA 修饰的新视角,我们或许能积累癌症分子生物学方面的知识,并通过诊断和治疗为人类健康做出贡献。
{"title":"Recent advances in noncoding RNA modifications of gastrointestinal cancer.","authors":"Tomoaki Hara, Sikun Meng, Yasuko Arao, Yoshiko Saito, Kana Inoue, Sarah Rennie, Ken Ofusa, Yuichiro Doki, Hidetoshi Eguchi, Toru Kitagawa, Hideshi Ishii","doi":"10.1111/cas.16380","DOIUrl":"https://doi.org/10.1111/cas.16380","url":null,"abstract":"<p><p>Elucidating the mechanisms underlying cancer development and proliferation is important for the development of therapeutic methods for the complete cure of cancer. In particular, the identification of diagnostic markers for early detection and new therapeutic strategies for refractory gastrointestinal cancers are needed. Various abnormal phenomena occur in cancer cells, such as functional changes of proteins, led by genomic mutations, and changes in gene expression due to dysregulation of epigenetic regulation. This is no exception for noncoding RNA (ncRNA), which do not encode proteins. Recent reports have revealed that microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA) are deeply involved in cancer progression. These ncRNAs have attracted attention as gene expression regulatory molecules. Recent advances in technology have made it possible not only to read DNA and RNA sequences but also to study the modification state of each base. In particular, comprehensive analysis of N6-methyladenosine (m<sup>6</sup>A) has been performed by many research groups, with multiple studies reporting that m<sup>6</sup>A modifications of specific genes are associated with cancer progression. Based on the above, this review examines how ncRNA modifications are related to cancer progression in gastrointestinal cancers such as colorectal and pancreatic cancer. We also discuss enzyme inhibitors that have been reported to have drug discovery potential targeting m<sup>6</sup>A modifications. By utilizing the new perspective of ncRNA modification, we may be able to accumulate knowledge on the molecular biology of cancer and contribute to human health through diagnosis and treatment.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noncanonical TCA cycle fosters canonical TCA cycle and mitochondrial integrity in acute myeloid leukemia. 非规范 TCA 循环促进急性髓性白血病中规范 TCA 循环和线粒体的完整性。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-10-31 DOI: 10.1111/cas.16347
Atsushi Watanabe, Chartsiam Tipgomut, Haruhito Totani, Kentaro Yoshimura, Tomohiko Iwano, Hamed Bashiri, Lee Hui Chua, Chong Yang, Toshio Suda

Cancer cells rely on mitochondrial oxidative phosphorylation (OXPHOS) and the noncanonical tricarboxylic acid (TCA) cycle. In this paper, we shed light on the vital role played by the noncanonical TCA cycle in a host-side concession to mitochondria, especially in highly energy-demanding malignant tumor cells. Inhibition of ATP-citrate lyase (ACLY), a key enzyme in the noncanonical TCA cycle, induced apoptosis by increasing reactive oxygen species levels and DNA damage while reducing mitochondrial membrane potential. The mitochondrial membrane citrate transporter inhibitor, CTPI2, synergistically enhanced these effects. ACLY inhibition reduced cytosolic citrate levels and CTPI2 lowered ACLY activity, suggesting that the noncanonical TCA cycle is sustained by a positive feedback mechanism. These inhibitions impaired ATP production, particularly through OXPHOS. Metabolomic analysis of mitochondrial and cytosolic fractions revealed reduced levels of glutathione pathway-related and TCA cycle-related metabolite, except fumarate, in mitochondria following noncanonical TCA cycle inhibition. Despite the efficient energy supply to the cell by mitochondria, this symbiosis poses challenges related to reactive oxygen species and mitochondrial maintenance. In conclusion, the noncanonical TCA cycle is indispensable for the canonical TCA cycle and mitochondrial integrity, contributing to mitochondrial domestication.

癌细胞依赖线粒体氧化磷酸化(OXPHOS)和非典型三羧酸(TCA)循环。在本文中,我们揭示了非典型三羧酸循环在宿主侧向线粒体让步中扮演的重要角色,尤其是在高能量需求的恶性肿瘤细胞中。抑制非典型 TCA 循环中的关键酶 ATP 柠檬酸酶(ACLY)会增加活性氧水平和 DNA 损伤,同时降低线粒体膜电位,从而诱导细胞凋亡。线粒体膜柠檬酸盐转运体抑制剂 CTPI2 协同增强了这些效应。ACLY 抑制剂降低了细胞膜柠檬酸盐水平,而 CTPI2 则降低了 ACLY 的活性,这表明非典型 TCA 循环是通过正反馈机制维持的。这些抑制作用损害了 ATP 的产生,尤其是通过 OXPHOS 产生的 ATP。线粒体和细胞质组分的代谢组学分析表明,非典型 TCA 循环抑制后,线粒体中谷胱甘肽途径相关代谢物和 TCA 循环相关代谢物(富马酸除外)的水平降低。尽管线粒体能有效地为细胞提供能量,但这种共生关系也带来了与活性氧和线粒体维护有关的挑战。总之,非典型 TCA 循环对典型 TCA 循环和线粒体的完整性不可或缺,有助于线粒体的驯化。
{"title":"Noncanonical TCA cycle fosters canonical TCA cycle and mitochondrial integrity in acute myeloid leukemia.","authors":"Atsushi Watanabe, Chartsiam Tipgomut, Haruhito Totani, Kentaro Yoshimura, Tomohiko Iwano, Hamed Bashiri, Lee Hui Chua, Chong Yang, Toshio Suda","doi":"10.1111/cas.16347","DOIUrl":"10.1111/cas.16347","url":null,"abstract":"<p><p>Cancer cells rely on mitochondrial oxidative phosphorylation (OXPHOS) and the noncanonical tricarboxylic acid (TCA) cycle. In this paper, we shed light on the vital role played by the noncanonical TCA cycle in a host-side concession to mitochondria, especially in highly energy-demanding malignant tumor cells. Inhibition of ATP-citrate lyase (ACLY), a key enzyme in the noncanonical TCA cycle, induced apoptosis by increasing reactive oxygen species levels and DNA damage while reducing mitochondrial membrane potential. The mitochondrial membrane citrate transporter inhibitor, CTPI2, synergistically enhanced these effects. ACLY inhibition reduced cytosolic citrate levels and CTPI2 lowered ACLY activity, suggesting that the noncanonical TCA cycle is sustained by a positive feedback mechanism. These inhibitions impaired ATP production, particularly through OXPHOS. Metabolomic analysis of mitochondrial and cytosolic fractions revealed reduced levels of glutathione pathway-related and TCA cycle-related metabolite, except fumarate, in mitochondria following noncanonical TCA cycle inhibition. Despite the efficient energy supply to the cell by mitochondria, this symbiosis poses challenges related to reactive oxygen species and mitochondrial maintenance. In conclusion, the noncanonical TCA cycle is indispensable for the canonical TCA cycle and mitochondrial integrity, contributing to mitochondrial domestication.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver". 对 "miR-203 抑制促进再生肝脏中残留肝细胞癌的增殖和转移 "的更正。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-10-30 DOI: 10.1111/cas.16361
{"title":"Correction to \"miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver\".","authors":"","doi":"10.1111/cas.16361","DOIUrl":"https://doi.org/10.1111/cas.16361","url":null,"abstract":"","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) Exert Their Anti-proliferative Activity by Interfering With Akt-mTOR Signaling and bax:bcl-2 Ratio Modulation in Cells From Chronic Myeloid Leukemic Patients. 返回:吡咯并[1,2-b][1,2,5]苯并噻二氮卓(PBTDs)通过干扰慢性骨髓性白血病患者细胞中 Akt-mTOR 信号传导和 bax:bcl-2 比率调节发挥抗增殖活性。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2024-10-30 DOI: 10.1111/cas.16390

Retraction: C. Di Stefano, G. Marfe, M. M. Trawinska, P. Sinibaldi-Salimei, R. Silvestri, S. Amadori and E. Abruzzese, "Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) Exert Their Anti-proliferative Activity by Interfering With Akt-mTOR Signaling and bax:bcl-2 Ratio Modulation in Cells From Chronic Myeloid Leukemic Patients," Cancer Science 101, no. 4 (2010): 991-1000, https://doi.org/10.1111/j.1349-7006.2010.01490.x. The above article, published online on 07 January 2010 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Masanori Hatakeyama; the Japanese Cancer Association; and John Wiley & Sons Australia, Ltd. The retraction has been agreed due to several instances of duplications of western blot bands observed in Figures 3, 4, 5 and 8. Furthermore, splicing and deletion of bands was uncovered in Figures 4 and 7 respectively. Finally, western blot bands presented in Figure 4 was also found published earlier in another article. The authors provided partial raw data but the inconsistencies found could not be resolved on this basis. Due to the extent and nature of the duplications, the editors consider the results and conclusions of this study invalid.

撤回:C. Di Stefano、G. Marfe、M. M. Trawinska、P. Sinibaldi-Salimei、R. Silvestri、S. Amadori 和 E. Abruzzese,"吡咯并[1,2-b][1,2,5]苯并噻二氮卓(PBTDs)发挥抗增殖作用"。Abruzzese, "Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) Exert Their Anti-proliferative Activity by Interfering With Akt-mTOR Signaling and bax:bcl-2 Ratio Modulation in Cells from Chronic Myeloid Leukemic Patients," Cancer Science 101, no.4 (2010):991-1000,https://doi.org/10.1111/j.1349-7006.2010.01490.x。上述文章于 2010 年 1 月 7 日在线发表于 Wiley Online Library (wileyonlinelibrary.com),经杂志主编 Masanori Hatakeyama、日本癌症协会和 John Wiley & Sons Australia, Ltd.协商,该文章已被撤回。同意撤稿的原因是在图 3、图 4、图 5 和图 8 中观察到多处 Western 印迹条带重复。此外,图 4 和图 7 分别发现了条带的拼接和删除。最后,图 4 中显示的 Western 印迹条带也是早先在另一篇文章中发现的。作者提供了部分原始数据,但发现的不一致之处无法据此解决。由于重复的程度和性质,编辑认为这项研究的结果和结论无效。
{"title":"RETRACTION: Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) Exert Their Anti-proliferative Activity by Interfering With Akt-mTOR Signaling and bax:bcl-2 Ratio Modulation in Cells From Chronic Myeloid Leukemic Patients.","authors":"","doi":"10.1111/cas.16390","DOIUrl":"https://doi.org/10.1111/cas.16390","url":null,"abstract":"<p><strong>Retraction: </strong>C. Di Stefano, G. Marfe, M. M. Trawinska, P. Sinibaldi-Salimei, R. Silvestri, S. Amadori and E. Abruzzese, \"Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) Exert Their Anti-proliferative Activity by Interfering With Akt-mTOR Signaling and bax:bcl-2 Ratio Modulation in Cells From Chronic Myeloid Leukemic Patients,\" Cancer Science 101, no. 4 (2010): 991-1000, https://doi.org/10.1111/j.1349-7006.2010.01490.x. The above article, published online on 07 January 2010 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Masanori Hatakeyama; the Japanese Cancer Association; and John Wiley & Sons Australia, Ltd. The retraction has been agreed due to several instances of duplications of western blot bands observed in Figures 3, 4, 5 and 8. Furthermore, splicing and deletion of bands was uncovered in Figures 4 and 7 respectively. Finally, western blot bands presented in Figure 4 was also found published earlier in another article. The authors provided partial raw data but the inconsistencies found could not be resolved on this basis. Due to the extent and nature of the duplications, the editors consider the results and conclusions of this study invalid.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1